Castle Biosciences, Inc. (CSTL)
33.47
-0.73
(-2.13%)
USD |
NASDAQ |
Aug 24, 16:00
33.50
+0.03
(+0.09%)
After-Hours: 20:00
Castle Biosciences Net Income (Quarterly) : -2.06M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.06M |
| March 31, 2026 | -14.52M |
| December 31, 2025 | -2.332M |
| September 30, 2025 | -0.501M |
| June 30, 2025 | 4.523M |
| March 31, 2025 | -25.85M |
| December 31, 2024 | 9.59M |
| September 30, 2024 | 2.269M |
| June 30, 2024 | 8.92M |
| March 31, 2024 | -2.534M |
| December 31, 2023 | -2.58M |
| September 30, 2023 | -6.905M |
| June 30, 2023 | -18.78M |
| March 31, 2023 | -29.20M |
| December 31, 2022 | -20.62M |
| September 30, 2022 | -20.25M |
| June 30, 2022 | -1.648M |
| Date | Value |
|---|---|
| March 31, 2022 | -24.62M |
| December 31, 2021 | -6.43M |
| September 30, 2021 | -11.79M |
| June 30, 2021 | -8.791M |
| March 31, 2021 | -4.28M |
| December 31, 2020 | -4.889M |
| September 30, 2020 | -4.589M |
| June 30, 2020 | -1.376M |
| March 31, 2020 | 0.57M |
| December 31, 2019 | 2.055M |
| September 30, 2019 | 5.849M |
| June 30, 2019 | -1.269M |
| March 31, 2019 | -1.358M |
| September 30, 2018 | -3.45M |
| June 30, 2018 | -3.155M |
| March 31, 2018 | -3.630M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| RadNet, Inc. | 20.25M |
| Lumexa Imaging Holdings, Inc. | 2.745M |
| Labcorp Holdings, Inc. | 299.10M |
| Quest Diagnostics, Inc. | 333.00M |
| OPKO Health, Inc. | -8.416M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 103.55M |
| Total Expenses (Quarterly) | 105.61M |
| EPS Diluted (Quarterly) | -0.0678 |
| Enterprise Value | 790.96M |
| Gross Profit Margin (Quarterly) | 74.29% |
| Profit Margin (Quarterly) | -1.99% |
| Earnings Yield | -1.94% |
| Normalized Earnings Yield | -2.131 |